EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations in Special Populations: A Call to Action

Marguerite L Monogue iD, James M Sanders iD, Nicholas J Mercuro iD, Crystal K Hodge iD, Esther Golnabi, Tyla Carettini, Christina F Yen, James B Cutrell iD

Open Forum Infectious Diseases · 03.03.2026 · 13 (3)

DOI: 10.1093/ofid/ofag093 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 03.03.2026. Verfasst von Marguerite L Monogue und 7 weiteren Autor:innen. Beteiligte Einrichtung: US Medical Affairs, bioMérieux, Salt Lake City, Utah, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacokinetic (PK) and pharmacodynamic (PD) variability in special populations can impact antimicrobial efficacy and safety. This review highlights the importance of PK/PD optimization in patients known to have altered PK, including those with obesity, cystic fibrosis, renal dysfunction, critical illness, transplantation, pregnancy, and/or significant burns. Historically, PK/PD data are underrepresented in these populations, leading to suboptimal dosing recommendations and increased risks of therapeutic failure or toxicity. Herein, we discuss key physiological alterations affecting antimicrobial PK/PD, regulatory challenges, and currently available solutions. To bridge these knowledge gaps, we advocate for broader patient inclusion in clinical trials, improved PK modeling, real-world data collection, and increased investment in precision dosing strategies. Addressing these issues has the potential to enhance patient outcomes, reduce antimicrobial resistance, and improve infectious diseases management. This review serves as a call to action for researchers, clinicians, and policymakers to prioritize PK/PD research in special patient populations.

Schlagwörter

Stichwörter der Autor:innen

antimicrobialcystic fibrosisobesitypharmacodynamicspharmacokinetics

Autor:innen und Institutionen

  • US Medical Affairs, bioMérieux, Salt Lake City, Utah, USA.
  • Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Division of Infectious Diseases, Department of Pharmacy, MaineHealth Maine Medical Center, Portland, Maine, USA.
  • Department of Pharmacotherapy, University of North Texas Health Science Center, Fort Worth, Texas, USA.
  • Division of Infectious Diseases, Department of Internal Medicine, MaineHealth Maine Medical Center, Portland, Maine, USA.

ORCID-Profile: Marguerite L Monogue, James M Sanders, Nicholas J Mercuro, Crystal K Hodge, James B Cutrell

Zitieren

APA

Monogue, M. L., Sanders, J. M., Mercuro, N. J., Hodge, C. K., Golnabi, E., Carettini, T., Yen, C. F., & Cutrell, J. B. (2026). Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations in Special Populations: A Call to Action. Open Forum Infectious Diseases, 13(3). https://doi.org/10.1093/ofid/ofag093

Vancouver

Monogue ML, Sanders JM, Mercuro NJ, Hodge CK, Golnabi E, Carettini T, et al. Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations in Special Populations: A Call to Action. Open Forum Infectious Diseases. 2026;13(3). doi:10.1093/ofid/ofag093

BibTeX
@article{Monogue2026,
  author = {Monogue, Marguerite L and Sanders, James M and Mercuro, Nicholas J and Hodge, Crystal K and Golnabi, Esther and Carettini, Tyla and Yen, Christina F and Cutrell, James B},
  title = {Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations in Special Populations: A Call to Action},
  journal = {Open Forum Infectious Diseases},
  year = {2026},
  volume = {13},
  number = {3},
  doi = {10.1093/ofid/ofag093}
}
Kostenlos starten →